Credit: Shutterstock
GSK wins expanded FDA approval for RSV shot in at-risk adults ages 50 to 59
The FDA on Friday expanded GSK’s RSV vaccine to people ages 50 to 59 who are at an increased risk of the virus, marking another …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
